|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
3
|
|
pubmed:dateCreated |
2004-8-12
|
|
pubmed:abstractText |
To characterize longitudinal hepatic toxicity of antiretroviral therapy in HIV-infected women with and without hepatitis C virus (HCV) infection, we measured alanine and aspartate aminotransferase values among women initiating highly active antiretroviral therapy (HAART). For 312 HIV/HCV coinfected women who received HAART for a mean of 1.8 years, the prevalence of elevated aminotransferase levels >3 times and >5 times the upper limit of normal (ULN) was low (<12% and <4%, respectively), and the prevalence of elevated aminotransferase levels declined over time. When we analyzed trends in aminotransferase levels according to type of HAART received among HCV-infected and uninfected women, we found that mean aminotransferase levels declined among 539 women receiving therapy with protease inhibitors (decreases of 5.34%-4.23% of the ULN per year; P values for trend of.007-.06), but mean values among 128 women receiving therapy with nonnucleoside reverse-transcriptase inhibitors remained stable (from decreases of 1.65% to increases of 7.57% of the ULN per year; P values of.19-.71). Our findings lend support to assertions that antiretroviral therapy is safe for women with HCV infection.
|
|
pubmed:grant |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Aug
|
|
pubmed:issn |
1537-6591
|
|
pubmed:author |
|
|
pubmed:issnType |
Electronic
|
|
pubmed:day |
1
|
|
pubmed:volume |
39
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
402-10
|
|
pubmed:dateRevised |
2009-11-19
|
|
pubmed:meshHeading |
pubmed-meshheading:15307009-Adult,
pubmed-meshheading:15307009-Alanine Transaminase,
pubmed-meshheading:15307009-Antiretroviral Therapy, Highly Active,
pubmed-meshheading:15307009-Aspartate Aminotransferases,
pubmed-meshheading:15307009-Biological Markers,
pubmed-meshheading:15307009-Drug-Induced Liver Injury,
pubmed-meshheading:15307009-Female,
pubmed-meshheading:15307009-HIV Infections,
pubmed-meshheading:15307009-HIV Protease Inhibitors,
pubmed-meshheading:15307009-Hepatitis C,
pubmed-meshheading:15307009-Humans,
pubmed-meshheading:15307009-Liver Diseases,
pubmed-meshheading:15307009-Longitudinal Studies,
pubmed-meshheading:15307009-Middle Aged,
pubmed-meshheading:15307009-Reverse Transcriptase Inhibitors
|
|
pubmed:year |
2004
|
|
pubmed:articleTitle |
Longitudinal effect of antiretroviral therapy on markers of hepatic toxicity: impact of hepatitis C coinfection.
|
|
pubmed:affiliation |
CORE Center/Cook County Hospital, Rush Medical College, Chicago, IL 60612, USA. Audrey_French@rush.edu
|
|
pubmed:publicationType |
Journal Article,
Research Support, U.S. Gov't, P.H.S.,
Multicenter Study
|
